Del Labs merger
This article was originally published in The Tan Sheet
Executive Summary
Kelso & Company subsidiary DLI Acquisition Corp. completes purchase of Del Labs following shareholder approval, Del announces Jan. 27. Under the $480 mil. transaction, Del will become a subsidiary of DLI Holding Corp. and will no longer be publicly traded. William McMenemy will replace Dan Wassong as president and CEO. The deal was first announced last July (1"The Tan Sheet" July 5, 2004, p. 10)...
You may also be interested in...
Church & Dwight Sinks Its Teeth Into Del Labs To Acquire Orajel
Church & Dwight will augment its oral care portfolio with the addition of Del Labs' Orajel topical analgesic brand under a proposed $465 mil. acquisition announced July 2
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.